This study demonstrates that modulation of IL-25 and IL-33 cytokines responsible for innate lymphoid cell 2 (ILC2) activation/function can differentially regulate ILC profiles at the vaccination site, in a vaccine route-dependent manner. Specifically, recombinant fowlpox (rFPV) vector-based vaccine co-expressing an adjuvant that transiently sequestered IL-25 (FPV-HIV-IL-25 binding protein), delivered intramuscularly (i. These inhibitor studies showed that in the context of i.n. viral vector vaccination, IL-25 plays a predominant role in early ILC development/regulation than IL-33, and likely acts as a master regulator of ILC. Our previous findings have indicated that level of IL-4/IL-13 at the vaccination site impacts the quality/avidity of T cell immunity. Taken together data suggest that IL-25 binding protein could be used as an effective i.m. not an i.n. adjuvant to enhance quality of vaccine-specific T cell immunity. These findings evoke the notion that route-dependent manipulation of ILCs according to the target pathogen could be exploited to design more effective vaccines against chronic pathogens in the future.
Introduction
Innate lymphoid cells (ILCs), are currently categorized into three main subsets (ILC1, ILC2, and ILC3), and considered as the innate equivalent of T cells lacking antigen-specific receptors [1] [2] [3] . ILC1 have shown to act as the first line of defense against some intracellular pathogens by secreting IFN-c and granulocytemacrophage colony-stimulating factor (GM-CSF) [3] [4] [5] . Discovery of ILC2 materialized when in RAG-deficient mice (lacking B and T cells), a subset of cells were found to express IL-5 and IL-13 in response to IL-25 [6] and decade later were termed as ILC2 [7] [8] [9] . Currently, ILC2 are classified into three main subsets, depending on their expression of ST2/IL-33R, IL-25R, and TSLPR [10] [11] [12] [13] . Interestingly, numerous studies have now shown that IL-33, IL-25, and TSLP differentially modulate ILC2 activity, specifically, in the context of tissue remodeling, allergy, and inflammation [14] [15] [16] [17] . ILC3 were initially described in human tissues as mucosalassociated lymphoid cells that expressed NKp44 and produce IL-22 [18] . But currently, three ILC3 subsets; lymphoid tissue inducer (LTi) cells, NKp46 À ILC3 and NKp46 + ILC3 have been identified based on the expression of various surface markers and cytokines they express [19] [20] [21] . ILC3 are mainly known to express IL-17A and IL-22 cytokines, but due to high plasticity have also shown to express IFN-c [3] . Recent studies indicate high plasticity between the different ILC subsets. The first observations of high plasticity of ILC were observed between ILC1/ILC3 and were shown to interchange under certain stimulatory conditions [22] [23] [24] can differentiate to ILC3 in the presence of IL-2, IL-23, and IL-1b [24] . Similarly, high plasticity of ILC2 has also been reported and shown to differentiate to ILC1 or ILC3 [21, 25, 26] . For example, ILC2s isolated form human blood, when cultured in the presence of IL-1b were shown to express IL-12 receptor and when IL-12 was then added to culture, these ILC2 were shown to express IFN-c, and down regulate IL-5 and IL-13 expression [26] . In another study following influenza virus infection, upon stimulation with IL-12 and IL-18, ILC2 were shown to down regulate GATA3 expression and convert to ILC1 and express IFN-c [27] . Moreover, under IL-6 and transforming growth factor-b (TGF-b), ILC2 has also shown to become ILC3-like cells and produce IL-17A [28] . Interestingly, ILC function/regulation in the context of inflammation and vaccination/infection have also been vastly different [29, 30] . Previous studies in our laboratory have established that intranasal vaccination with rFPV unadjuvanted vaccination induced ST2/IL-33R + ILC2 in the lung, whereas intramuscular vaccination induced IL-25R + ILC2 in muscle [29] . (Fig. S1 ), WT BALB/c mice were vaccinated intramuscularly (i.m.) with the unadjuvanted FPV-HIV vaccine and the FPV-HIV-IL-25BP adjuvanted vaccine, which sequestered IL-25 at the vaccination site muscle. Note that in this study, ILC cytokine expression was evaluated 24 h post vaccination, as in our previous studies peak ILCs activity was detected at this timepoint [29] . Firstly, when IL-13 expression by ILC2 was assessed, significantly lower expression of IL-13 was detected in FPV-HIV-IL-25BP vaccine compared to the control unadjuvanted group (p < 0.01) (Fig. 1a & (Fig. 1c & d) , and no significant differences in IL-17A and IL-22 production were observed between the two groups ( Fig. 1c & d 
Intranasal FPV-HIV-IL-25BP vaccination induced unique ILC2 subsets expressing IL-13 in lung
Knowing that lung ILC2s were mainly ST2/IL-33R + , next WT BALB/c mice were vaccinated intranasally (i.n.) with FPV-HIV-33BP, and unadjuvanted control and lung ILC subsets and their cytokine expression were evaluated at 24 h post vaccination. ILC subsets were gated as described previously [29] (Fig. S2) . Interestingly, transient sequestration of IL-33 at the lung mucosae did not alter the ILC2 profiles compared to the control vaccination ( 
Intranasal FPV-HIV-IL-25BP vaccination induced a novel ST2/IL-33R
À IL-25R À TSLPR À ILC2 subset expressing IL-13 and IL-4
There was an unexpected discovery with FPV-HIV-IL-25BP adjuvanted vaccination where a lineage À IL-25R À ST2/IL-33R À TSLPR À cell population that not only to expressed IL-13 but also IL-4 were detected (Fig. 4a-c) . This ILC2 subset, the IL-4 and IL-13 expression was much greater than the other three known ILC2 subsets (p < 0.0001) (Fig. 4d-f ) and interestingly, a small subset of these cells were also found to be double positive for both IL-13 and IL-4 (Fig. 4d ). These observations suggested that lineage
subset. As expected [3] , all ILC2 subsets did not express IL-17A or IFN-c (Fig. 4a-c (Fig. 4d) .
Discussion
Following intranasal FPV-HIV-IL-25BP vaccination, where IL-25 was temporarily sequestered from the vaccination site, significant impact on ILC development/function in lung mucosae were observed, similar to that of muscle following intramuscular vaccination. Specifically, in relation to lung ILC2, not only ST2/IL-33R ST2/IL-33R + ILC2 are resident in lung unlike IL-25R + ILC2, which are known to be ''inflammatory" ILC [28] and are recruited to the muscle following i.m. vaccination [29] . The current study demonstrated that transient inhibition of IL-25 at the vaccination site can promote some ILC2s at the lung mucosae to express both IL-13 as well as IL-4. Interestingly, the IL-4 expressing ILC2s induced by FPV-HIV-IL-25BP adjuvanted vaccination did not express IL-13, suggesting that these were two distinct ILC2 populations. Recent studies have also shown that addition of IL-25 and IL-33 can promote differential cytokine expression by lung ST2/IL-33R + ILC2. For example, when lung ST2/IL-33R + ILC2 were cultured in the presence of IL-25 in vitro, these cells were shown to produce elevated IL-13 but reduced IL-5 whereas the inverse was reported when cells were cultured in the presence of IL-33 [33, 34] . Furthermore, Chen et al using IL-13-GFP reporter mice have also shown that compared to IL-33, intranasal administration of recombinant IL-25 can induce elevated IL-13 expression by lung ILC2 [33] . Interestingly, the current study demonstrated that removal of IL-25 from the cell milieu can have profound impact on ILC2 differentiation (induction of numerous ILC2 subsets) including IL-13 and IL-4 expression, unlike overexpression of IL-25. Thus, these observations further supported the notion that IL-25 plays a dominant role in ILC2 development in lung compared to IL-33.
Our previous studies have shown that mucosal vaccination induced high avidity CD8 + T cells and this was associated with low level of IL-13 expressed by T cells [35] . In contrast, systemic vaccination induced low avidity CD8 + T cells associated with elevated level of IL-13 [35] . Transient inhibition of IL-4 and IL-13 at the vaccination site has shown to induce (i) T cells of high avidity [36] and (ii) unlike IL-13Ra2 adjuvanted vaccination IL-4R antagonist vaccination has also shown to induce excellent antibody differentiation [36, 37] , suggesting IL-13 plays an important role in modulating both T and B cell immunity [38, 39] . These studies also showed that level of IL-4/IL-13 at the vaccination site can significantly alter the activity of antigen presenting cells [40] . When trying to dissect which cells at the vaccination site produced IL-13, our previous studies have clearly established that ILC2 were the major source of IL-13 at the vaccination site 24 h post viral vector vaccination [29] . Interestingly, low IL-4/IL-13 levels have been associated with recruitment of CD11b + CD103 À conventional DCs, and induction of high avidity HIV-specific CD8 + T cells [40] . Intranasal FPV-HIV-IL-25BP adjuvanted vaccination induced significantly elevated IL-4 and IL-13 expression by ILC2 at the lung mucosae 24 h post vaccination (Table 1) . Taken together our previous findings, the current data suggest that sequestration of IL-25 at the lung mucosae may be detrimental for the induction of high 
the number of cells in each quadrant is indicated within brackets below the cell percentage (a). Graph represents percentages of the different ILC2 subsets following unadjuvanted FPV-HIV, IL-25BP and IL-33BP adjuvanted vaccinations (b & c). The representative FACS plots and graphs indicate the three different ILC2 subsets expressing IL-13 and/or IL-4 (d-h). The error bars represent the mean and standard deviation (s.d.)
. The p-values were calculated using GraphPad Prism software (version 6.05 for Windows). * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. For each group experiments were repeated minimum three times. avidity T cells. However, intramuscular FPV-HIV-IL-25BP vaccination significantly inhibited both IL-4 and IL-13 expression by ILC2 in muscle ( Table 1 ), suggesting that IL-25BP could be a highly efficacious intramuscular adjuvant than an intranasal adjuvant.
Interestingly, FPV-HIV-IL-25BP adjuvanted vaccination not only manipulated the ILC2 differentiation/function but also ILC1 and ILC3 at the vaccination site. This was highly unexpected as cytokine IL-25 was thought to be an activator of ILC2 but not ILC1/ ILC3 [31] . Surprisingly, compared to the unadjuvanted rFPV vaccination, transient removal of IL-25 at the muscle and lung mucosae induced elevated expression of IL-17A by lineage À ST2/IL-33R (Table 1) .
Although following intranasal FPV-HIV-IL-33BP vaccination, no significant differences in the lung ILC2 subsets or their IL-13 were calculated using GraphPad Prism software (version 6.05 for Windows). * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. For each group experiments were repeated minimum three times. [48] . In conclusion, current findings further substantiate that the adjuvants used and the route of delivery play an important role in modulating ILC activity and ILC-driven cytokine expression at the vaccinations site, and these early events need to be seriously taken into consideration when designing effective vaccines against chronic pathogens.
Methods

Mice
5-7-week-old pathogen free female wild type (WT) BALB/c mice were obtained from the Australian Phenomics Facility, the Australian National University. All animals were maintained, and experiments were performed in accordance with the Australian NHMRC guidelines within the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and in accordance with guidelines approved by the Australian National University Animal Experimentation and Ethics Committee (AEEC). This study was approved by the AEEC and listed under ANU ethics protocol numbers A2014/14 and A2017/15.
Immunization and preparation of lung and muscle lymphocytes
In this study, 1 Â Sonifier 450 on ice just prior to administration. Lungs or quadriceps muscle tissues were harvested in 2 ml of complete RPMI 24 h post immunization, and single cell suspensions were prepared as per described previously [29] . Briefly, lungs were cut into small pieces and enzymatically digested for 45 min at 37°C in digestion buffer containing 1 mg/ml collagenase (Sigma-Aldrich, St Louis, MO), 1.2 mg/ml Dispase (Gibco, Auckland, NZ), 5 Units/ml DNase (Calbiochem, La Jolla, CA) in complete RPMI. Samples were mashed and passed through a falcon cell strainer and resulting lung cell suspensions were then lysed with RBCs, washed and once again passed through gauze to remove debris. Quadriceps muscle tissues were also cut into small pieces and digested with 0.5 mg/ml collagenase, 2.4 mg/ml Dispase, 5 Units/ml DNase and complete RPMI for 30 min at 37°C, passed through a falcon cell strainer (without mashing to avoid creating smaller debris) and gauze to remove debris similar to lung. The cells were then suspended in complete RPMI and rested overnight at 37°C with 5% CO 2 as per our previous studies [29, 36] . All cells were treated with 1% Brefeldin A for 5 h prior to staining and analysing using multi-colour flow cytometry. 
Statistical analysis
In this study, cell numbers were calculated using the formula (cytokine expressing cells/number of CD45 + cells) Â 10
6
. The graphs represent the mean and standard deviation (s.d.). The pvalues were calculated using GraphPad Prism software (version 6.05 for Windows). One-way ANOVA or two-way ANOVA using Tukey's multiple comparisons test were used to calculate statistical significance. The P-values were denoted as follows: nsp ! 0.05, * -p < 0.05, ** -p < 0.01. *** -p < 0.001, **** -p < 0.0001. In this study, n = 4-6 mice per group were used and all experiments were repeated at least three times.
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